Viral Vector Market was worth USD 0.60 billion in 2022 and is estimated to grow at a CAGR of 19.7% in the forecasted period. The forecasted revenue hints at a growth of around 2.13 bill… Read More

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced its entry into an exclu… Read More

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company recently announced that the… Read More

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its CFO Ryan Confer w… Read More

U.S.-based gene therapy developer Genprex, Inc. is developing new therapies for fighting cancer tumors and diabetes The company’s gene therapies for battling types 1 and 2 dia… Read More

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China N… Read More

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its appointment of Suzanne… Read More

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the United States Foo… Read More

Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. FDA Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combin… Read More

Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers… Read More

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its entry into definitive a… Read More

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collab… Read More

Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial The P… Read More

Genprex Chief Medical Officer, Dr. Mark Berger, was featured in a recent Bell2Bell Podcast episode, where he discussed the company’s recent announcements In May, the company r… Read More

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in comb… Read More

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced that its research colla… Read More

Positive preclinical data was presented for the NPRL2 tumor suppressor gene The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant… Read More

Getting into the pharmaceutical industry in Austin is one of the best things to do in the city. There are a lot of opportunities for you to choose from. You can find a job that you will enjo… Read More

New York, New York--(Newsfile Corp. - April 12, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio broadcast titled, "Potential Blockbuster Gene Therapy Pr… Read More

Genprex, Inc. closed its IPO on April 3, 2018, selling 1.28 million shares of common stock at a price of $5.00 per share, and trades under the symbol “GNPX” (NasdaqCM: GNPX). Th… Read More

  Industry Report – Biotechnology Industry Overview July 2020, 07/10/2020   Industry Report – Metals & Mining Second Quarter 2020 Review and Outlook, 07/10/2020 &n… Read More

Dearest readers, followers and friends.To recharge batteries, I will take few days off, from February 24th to 26th and back to office on Thursday. Snowboard/family time next week in Sierra N… Read More

( click to enlarge )Ekso Bionics Holdings Inc (NASDAQ: EKSO) chart looks to be making a turn here. The stock has been beaten down this year and almost six months ago traded for over $4 a sha… Read More